J. Frew

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 519 citations · Full text

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 280 citations · Full text

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Julia Scarisbrick, Pietro Quaglino, H. Miles Prince et al. · British Journal of Dermatology · 2018 · 216 citations · Full text

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer

Thomas Powles, Robert Huddart, Tony Elliott et al. · Journal of Clinical Oncology · 2017 · 194 citations

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Nicholas van As, Clare Griffin, Alison Tree et al. · New England Journal of Medicine · 2024 · 172 citations · Full text